Intravenous magnesium sulfate for the management of severe hand, foot, and mouth disease with autonomic nervous system dysregulation in Vietnamese children: Study protocol for a randomized controlled trial

Trials

Volumn 17, Issue 1, 2016, Pages

  Qui, Phan Tu ^a,b   Khanh, Truong Huu ^c   Trieu, Huynh Trung ^a   Giang, Pham Thanh ^a   Bich, Nguyen Ngoc ^a   Thoa, Le Phan Kim ^c   Nhan, Le Nguyen Thanh ^c   Sabanathan, Saraswathy ^b,d   Van Doorn, Rogier ^b,d   Toan, Nguyen Duc ^b   Merson, Laura ^b,d   Dung, Nguyen Thi Phuong ^b   Khanh, Lam Phung ^b   Wolbers, Marcel ^b,d   Hung, Nguyen Thanh ^c   Chau, Nguyen Van Vinh ^a   Wills, Bridget ^b,d  

^a UNIVERSITY COLLEGE LONDON HOSPITALS   (United Kingdom)

^b OXFORD UNIVERSITY CLINICAL RESEARCH UNIT   (Viet Nam)

^c CHILDREN S HOSPITAL 1   (Viet Nam)

^d UNIVERSITY OF OXFORD   (United Kingdom)

Author keywords

And mouth disease; Brainstem encephalitis; Foot; Hand; Magnesium sulfate; Randomized controlled trial

Indexed keywords

MAGNESIUM SULFATE; PLACEBO; MILRINONE;

ARTICLE; AUTONOMIC NEUROPATHY; CHILD; CONTINUOUS INFUSION; CONTROLLED STUDY; DISEASE COURSE; DISEASE SEVERITY; DOUBLE BLIND PROCEDURE; DRUG DOSE INCREASE; DRUG EFFECT; DRUG EFFICACY; DRUG RESPONSE; DRUG SAFETY; HAND FOOT AND MOUTH DISEASE; HUMAN; HYPERTENSION; LENGTH OF STAY; LOADING DRUG DOSE; MAJOR CLINICAL STUDY; RANDOMIZED CONTROLLED TRIAL; VIETNAMESE; AUTONOMIC NERVOUS SYSTEM DISEASES; CLINICAL PROTOCOL; COMPLICATION; HAND, FOOT AND MOUTH DISEASE; INFORMED CONSENT; INTRAVENOUS DRUG ADMINISTRATION; SAMPLE SIZE; STATISTICAL ANALYSIS;

AUTONOMIC NERVOUS SYSTEM DISEASES; CLINICAL PROTOCOLS; DATA INTERPRETATION, STATISTICAL; DOUBLE-BLIND METHOD; HAND, FOOT AND MOUTH DISEASE; HUMANS; INFORMED CONSENT; INJECTIONS, INTRAVENOUS; MAGNESIUM SULFATE; MILRINONE; SAMPLE SIZE;

EID: 84958535322     PISSN: None     EISSN: 17456215     Source Type: Journal    
DOI: 10.1186/s13063-016-1215-6     Document Type: Article

References (29)

1. Solomon T, Lewthwaite P, Perera D, Cardosa MJ, McMinn P, Ooi MH. Virology, epidemiology, pathogenesis, and control of enterovirus 71. Lancet Infect Dis. 2010;10:778-90.
2. Vietnam Ministry of Health: Health Statistics Yearbook 2011. Hanoi: Medical Publisher; 2012:175-76
3. WHO. A Guide to Clinical Management and Public Health Response for Hand Foot Mouth Disease (HFMD) 2010. http://www.wpro.who.int/emerging_diseases/documents/HFMDGuidance/en/. Accessed 2 Dec 2011.
4. Fu YCCC, Chiu YT, Hsu SL, Hwang B, Jan SL, Chen PY, et al. Cardiac complications of enterovirus rhombencephalitis. Arch Dis Child. 2004;89:368-73.
5. Fu YC, Chi CS, Chiu YT, Hsu SL, Hwang B, Jan SL, Chen PY, Huang FL, Chang Y. Cardiac complications of enterovirus rhombencephalitis. Arch Dis Child. 2004;89(4):368-73. PubMed PMID: 15033850; PubMed Central PMCID: PMC1719879.
6. Fu YC, Chi CS, Lin NN, Cheng CC, Jan SL, Hwang B, Hsu SL, Gong CL, Chen YT, Chiu YT. Comparison of heart failure in children with enterovirus 71 rhombencephalitis and cats with norepinephrine cardiotoxicity. Pediatr Cardiol. 2006;27(5):577-84. PubMed PMID: 16933070.
7. Wang S-M, Lei H-Y, Yu C-K, Wang J-R, Su I-J, Liu C-C. Acute Chemokine Response in the Blood and Cerebrospinal Fluid of Children with Enterovirus 71-Associated Brainstem Encephalitis. J Infect Dis. 2008;198:1-5.
8. Zubcevic J, Waki H, Raizada MK, Paton JFR. Autonomic-Immune-Vascular Interaction: An Emerging Concept for Neurogenic Hypertension. Hypertension. 2011;57:1026-33.
9. Wang SM, Lei HY, Huang MC, Wu JM, Chen CT, Wang JN, et al. Therapeutic efficacy of milrinone in the management of enterovirus 71-induced pulmonary edema. Pediatr Pulmonol. 2005;39:219-23.
10. Chi CY, Khanh TH, le PK T, Tseng FC, Wang SM, Thinh le Q, et al. Milrinone Therapy for Enterovirus 71-Induced Pulmonary Edema and/or Neurogenic Shock in Children: A Randomized Controlled Trial. Crit Care Med. 2013;41:1-7.
11. Vietnamese Ministry of Health: Guideline for HFMD Management. Hà No i, 2012. http://benhnhietdoi.vn/data/files/documents/QD.1003.BYT.20.3.2012_Huong_dan_chan_doan_va_dieu_tri_benh_tay_chan_mieng.pdf.Accessed 9 April 2012.
12. Drugs.com. Milrinone injection - FDA prescribing information, side effects and uses. http://www.drugs.com/pro/milrinone-injection.html. Accessed 16 Feb 2016.
13. Smith AH, Owen J, Borgman KY, Fish FA, Kannankeril PJ. Relation of milrinone after surgery for congenital heart disease to significant postoperative tachyarrhythmias. Am J Cardiol. 2011;108:1620-4.
14. Thwaites CL, Yen LM, Cordon SM, Thwaites GE, Loan HT, Thuy TT, et al. Effect of magnesium sulphate on urinary catecholamine excretion in severe tetanus. Anaesthesia. 2008;63:719-25.
15. Thwaites CL, Yen LM, Cordon SM, Binh NT, Nga NTN, White NJ, et al. Urinary catecholamine excretion in tetanus. Anaesthesia. 2006;61:355-9.
16. Thwaites CL, Yen LM, Loan HT, Thuy TT, Thwaites GE, Stepniewska K, Soni N, White NJ, Farrar JJ. Magnesium sulphate for treatment of severe tetanus: a randomised controlled trial. Lancet. 2006;368(9545):1436-43. PubMed PMID: 17055945.
17. James MF, Beer RE, Esser JD. Intravenous magnesium sulfate inhibits catecholamine release associated with tracheal intubation. Anesth Analg. 1989;68:772-6.
18. Rowe BHBJ, Bourdon C, Bota G, Blitz S, Camargo CA. Magnesium sulfate for treating exacerbations of acute asthma in the emergency department (Review). The Cochrane Library. 2009;3:25.
19. Tolsa JF, Cotting J, Sekarski N, Payot M, Micheli JL, Calame A. Magnesium sulphate as an alternative and safe treatment for severe persistent pulmonary hypertension of the newborn. Arch Dis Child. 1995;72:F184-7.
20. Jones NAJS. Management of life-threatening autonomic hyper-reflexia using magnesium sulphate in a patient with a high spinal cord injury in the intensive care unit. Br J Anaesth. 2002;88:434-8.
21. Maehama TIH, Kanazawa K. Management of autonomic hyperreflexia with magnesium sulfate during labor in a woman with spinal cord injury. Am J Obstet Gynecol. 2000;183:492-3.
22. Smyth RMSP, Armstrong N, Duley L. Magpie Trial in the UK: methods and additional data for women and children at 2 years following pregnancy complicated by pre-eclampsia. BMC Pregnancy Childbirth. 2009;9.
23. Touyz RM. Role of magnesium in the pathogenesis of hypertension. Mol Asp Med. 2003;24:107-36.
24. Sugimoto J, Romani AM, Valentin-Torres AM, Luciano AA, Ramirez Kitchen CM, Funderburg N, et al. Magnesium Decreases Inflammatory Immunomodulatory Mechanism: A Novel Innate Cytokine Production. J Immunol. 2012;188:6338-46.
25. Muroi CBJ, Hugelshofer M, Seule M, Mishima K, Keller E. Magnesium and the inflammatory response: potential pathophysiological implications in the management of patients with aneurysmal subarachnoid hemorrhage? Magnes Res. 2012;25:64-71.
26. Ho JJRG. Magnesium sulfate for persistent pulmonary hypertension of the newborn. The Cochrane Library. 2010; 3
27. National High Blood Pressure Education Program Working Group on High Blood Pressure in Children and Adolescents. Pediatrics. 2004; 114:555.
28. Flynn JT. Management of hypertensive emergencies and urgencies in children. http://www.uptodate.com/contents/management-of-hypertensive-emergencies-and-urgencies-in-children?source=search_result&search=Management+of+hypertensive+emergencies+and+urgencies+in+children&selectedTitle=1%7E150. Accessed 16 Nov 2012.
29. National Cancer Institute: Common Terminology Criteria for Adverse Events (CTCAE). version 4.03. 2010. http://evs.nci.nih.gov/ftp1/CTCAE/CTCAE_4.03_2010-06-14_QuickReference:5x7.pdf. Accessed 17 Feb 2013.